Envoy Medical Expands Intellectual Property Portfolio to 99 Patents with New U.S. and Hong Kong Patent Grants

New Patents Cover Cochlear Implant Electrode Impedance Diagnostics and Integrated Signal Analysis Functionality

White Bear Lake, Minnesota--(Newsfile Corp. - November 17, 2026) - Envoy Medical®, Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health and neuroprosthetics company pioneering fully implanted hearing solutions, today announced it has been granted two additional patents in the United States and Hong Kong, bringing its intellectual property portfolio to 99 patents. In addition, the Company has 24 pending foreign applications and eight pending U.S. applications, further expanding its intellectual property portfolio.

The United States Patent and Trademark Office granted U.S. Patent No. 12,773,553 to Envoy Medical, titled "Cochlear Implant System with Electrode Impedance Diagnostics." The patent covers stimulation path impedance and compliance voltages in cochlear implant systems. It describes a system that can adjust a prescribed current when the compliance voltage associated with applying that current differs sufficiently from an applied compliance voltage.

The Hong Kong Patent Office granted Hong Kong Patent No. HK40105814 to Envoy Medical, titled "Cochlear Implant System with Integrated Signal Analysis Functionality." The patent covers using an external device to indicate a signal within a fully implantable cochlear implant system for analysis, receiving a representative signal from the system, and outputting a representation of that signal.

Expanding Global Intellectual Property Portfolio

Envoy Medical's intellectual property portfolio spans different technologies and ideas supporting current developments as well as future improvements of its fully implanted hearing platform technologies, including sensing, signal processing, implantation and system integration.

Envoy Medical's global patent portfolio now consists of:

  • 41 U.S. granted patents
  • 58 foreign granted patents
  • 99 total granted patents globally
  • 32 pending applications (24 foreign and 8 U.S.)

The foreign patent count includes, for granted European cases, the European Patent ("EP") separately from and in addition to corresponding individual country validations and unitary patents.

To be added to the Envoy Medical email distribution list, please email Envoy@kcsa.com with COCH in the subject line.

About Envoy Medical, Inc.
Envoy Medical (NASDAQ: COCH) is a hearing health and neuroprosthetics company focused on providing innovative technologies across the hearing loss spectrum. Envoy Medical has pioneered one-of-a-kind, fully implanted devices for hearing loss, including its fully implanted Esteem® active middle ear implant, commercially available in the U.S. since 2010, and the fully implanted Acclaim® cochlear implant, an investigational device. Envoy Medical is dedicated to pushing hearing technology beyond the status quo to improve access, usability, compliance, and ultimately quality of life.

About the Fully Implanted Acclaim® Cochlear Implant
We believe the fully implanted Acclaim Cochlear Implant ("Acclaim CI") is a first-of-its-kind hearing device. Envoy Medical's fully implanted technology includes a sensor designed to leverage the natural anatomy of the ear instead of a microphone to capture sound.

The Acclaim CI is designed to address severe to profound sensorineural hearing loss that is not adequately addressed by hearing aids. The Acclaim CI is expected to be indicated for adults who have been deemed adequate candidates by a qualified physician.

The Acclaim Cochlear Implant received the Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) in 2019.

The Acclaim CI is currently under investigation as part of a U.S.-based pivotal clinical trial. For more information on the trial, visit www.envoymedical.com/acclaim-pivotal.

CAUTION: The fully implanted Acclaim Cochlear Implant is an investigational device. Limited by Federal (or United States) law to investigational use.

About the Esteem® Fully Implanted Active Middle Ear Implant (FI-AMEI)
The Esteem fully implanted active middle ear implant (FI-AMEI) is the only FDA-approved, fully implanted* hearing device for adults diagnosed with moderate to severe sensorineural hearing loss allowing for 24/7 hearing capability using the ear's natural anatomy. The Esteem FI-AMEI hearing implant is invisible and requires no externally worn components and nothing is placed in the ear canal for it to function. Unlike hearing aids, you never put it on or take it off. You can't lose it. You don't clean it. The Esteem FI-AMEI hearing implant offers true 24/7 hearing.

*Once activated, the external Esteem FI-AMEI Personal Programmer is not required for daily use.

Important safety information for the Esteem FI-AMEI can be found at: https://www.envoymedical.com/safety-information.

Additional Information and Where to Find It
Copies of the documents filed by Envoy Medical with the SEC may be obtained free of charge at the SEC's website at www.sec.gov.

Click here for important information.